In:
Journal of Alzheimer's Disease, IOS Press, Vol. 49, No. 2 ( 2015-11-27), p. 271-276
Kurzfassung:
We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer’s disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.
Materialart:
Online-Ressource
ISSN:
1387-2877
,
1875-8908
Sprache:
Unbekannt
Verlag:
IOS Press
Publikationsdatum:
2015
ZDB Id:
2070772-1